Deferred Revenue was BioAge Labs’s largest revenue line in fiscal 2025, bringing in $6.70M of $8.90M (75%).
| Counterparty Name | FY 2025 |
|---|---|
| Deferred Revenue | $6.70M |
| Reimbursable Costs | $2.20M |
| Total | $8.90M |
BioAge Labs brought in $8.90M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Deferred Revenue was the largest at $6.70M (75.3%), ahead of Reimbursable Costs at $2.20M (24.7%).
BioAge Labs (BIOA) reports its revenue by counterparty name. In fiscal 2025, Deferred Revenue was its largest revenue line, bringing in $6.70M (75.3% of the total), followed by Reimbursable Costs at $2.20M (24.7%).
Deferred Revenue was BioAge Labs' largest revenue line in fiscal 2025, bringing in $6.70M, or 75.3% of the $8.90M total across its two revenue lines.
Every figure comes from BioAge Labs' annual financial filings, as reported. Each line keeps the name BioAge Labs gives it, and years follow its fiscal calendar.
BioAge Labs' revenue by counterparty name goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.